Delafloxacin meglumine is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated in skin disease. It is grouped under the following drug class(es): Fluoroquinolones, Quinolones and Topoisomerase inhibitors. Its therapeutic use is listed as anti-infectives, antibacterials and antibiotics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Baxdela (TN) and ABT-492 meglumine. Its PubChem CID is 11578213.
Delafloxacin meglumine
| CAS No | 352458-37-8 |
|---|---|
| Molecular Formula | C25H29ClF3N5O9 |
| Molecular Weight | 636.0 g/mol |
| Synonyms | 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Delafloxacin meglumine is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated in skin disease. It is grouped under the following drug class(es): Fluoroquinolones, Quinolones and Topoisomerase inhibitors.
The listed CAS number is 352458-37-8.
The listed molecular formula is C25H29ClF3N5O9.
The listed molecular weight is 636.0 g/mol.
1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol.
The source lists Baxdela (TN) and ABT-492 meglumine.